Repros Therapeutics Inc. (NASDAQ:RPRX) shares dropped 6.5% during trading on Wednesday . The company traded as low as $0.65 and last traded at $0.65. Approximately 1,409,880 shares were traded during mid-day trading, an increase of 32% from the average daily volume of 1,071,400 shares. The stock had previously closed at $0.69.

Separately, Laidlaw lowered Repros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, July 21st.

The stock’s market capitalization is $23.73 million. The company’s 50-day moving average price is $0.34 and its 200 day moving average price is $0.56.

Repros Therapeutics (NASDAQ:RPRX) last announced its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.14. Repros Therapeutics had a negative return on equity of 412.64% and a negative net margin of 56,062.07%. The firm had revenue of $0.01 million during the quarter. Equities research analysts predict that Repros Therapeutics Inc. will post ($1.07) EPS for the current fiscal year.

An institutional investor recently raised its position in Repros Therapeutics stock. Allegis Investment Advisors LLC lifted its holdings in shares of Repros Therapeutics Inc. (NASDAQ:RPRX) by 8.9% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 398,792 shares of the biotechnology company’s stock after buying an additional 32,602 shares during the period. Allegis Investment Advisors LLC owned about 1.49% of Repros Therapeutics worth $183,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 14.52% of the company’s stock.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at

Repros Therapeutics Company Profile

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Stock Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related stocks with our FREE daily email newsletter.